Acupuncture in shoulder pain and functional impairment after neck dissection: A prospective randomized pilot study

OBJECTIVES/HYPOTHESIS: The efficacy of conventional physiotherapy and antiinflammatory/analgesic drugs in the management of shoulder pain and functional disability following neck dissection is often disappointing. Acupuncture is a safe and well-tolerated method. We report the results regarding our pilot trial of acupuncture versus conventional care in the management of postoperative shoulder pain and dysfunction after neck dissection. STUDY DESIGN: Pilot study. METHODS: Patients at a tertiary university center with chronic pain or dysfunction attributed to neck dissection were randomly assigned to either weekly acupuncture or usual care (eg., physical therapy, analgesia, and/or antiinflammatory drugs) for 5 consecutive weeks. The Constant-Murley score, a composite measure of pain, function, and activities of daily living, was the primary outcome measure. As secondary end point, The Neck Dissection Impairment Index (NDII) was used to quantify site-specific, self-reported quality of life (QOL). RESULTS: After randomization, 48 patients completed the study (23 and 25 patients on acupuncture and control arms, respectively). Constant-Murley scores improved more in the acupuncture group (gain difference between groups 13.6, P < 0.01), a statistically significant improvement in site-specific QOL was also recorded at NDII (gain difference between groups 11.5, P < 0.01). CONCLUSION: Acupuncture is safe and effective; it should be introduced and offered to patients suffering from neck pain and dysfunction related to neck dissection

Refractory mucocutaneous leishmaniasis resolved with combination treatment based on intravenous pentamidine, oral azole, aerosolized liposomal amphotericin B, and intralesional meglumine antimoniate

Introduction: Mucocutaneous leishmaniasis (MCL) is a complication of tegumentary leishmaniasis, causing potentially life-threatening lesions in the ear, nose, and throat (ENT) region, and most commonly due to Leishmania (Viannia) braziliensis. We report a case of relapsing MCL in an Italian traveler returning from Argentina. Case description: A 65-year-old Italian male patient with chronic kidney disease, arterial hypertension, prostatic hypertrophy, and type-2 diabetes mellitus was referred for severe relapsing MCL acquired in Argentina. ENT examination showed severe diffuse pharyngolaryngeal edema and erythema, partially obstructing the airways. A nasopharyngeal biopsy revealed a lymphoplasmacytic inflammation and presence of Leishmania amastigotes, subsequently identified as L. (V.) braziliensis by hsp70 PCR-RFLP analysis and sequencing. Despite receiving four courses of liposomal amphotericine B (L-AmB) and two courses of miltefosine over a 2-year period, the patient presented recurrence of symptoms a few months after the end of each course.After the patient was referred to us, a combined treatment was started with intravenous pentamidine 4 mg/kg on alternate days for 10 doses, followed by one dose per week for an additional seven doses, intralesional meglumine antimoniate on the nasal lesion once per week for six doses, oral azoles for three months, and aerosolized L-AmB on alternate days for three months.The treatment led to regression of mucosal lesions and respiratory symptoms. Renal function temporarily worsened, and the addition of insulin was required to maintain glycemic compensation after pentamidine discontinuation. Conclusions: This case highlights the difficulties in managing a life-threatening refractory case of MCL in an Italian traveler with multiple comorbidities. Even though parenteral antimonial derivatives are traditionally considered the treatment of choice for MCL, they are relatively contraindicated in cases of chronic kidney disease.The required dose adjustment in cases of impaired renal function is unknown, therefore the use of alternative drugs is recommended. This case was resolved with combination treatment, including aerosolized L-AmB, which had never been used before for MCL

Mastoid obliteration in "canal wall down" or open tympanoplasty: from local flaps and autologous grafts to engineered biomaterials. Pilot study on the usability of a novel ceramic gum. L'obliterazione della mastoide nella timpanoplastica aperta: da lembi locali ed innesti di materiale autologo a biomateriali ingegnerizzati. Studio pilota sulla possibilita di impiego di una gomma ceramica di recente introduzione.

Canal wall down surgery remains the most common and least controversial operation for the treatment of cholesteatoma, providing a lower recurrence rate. The result is though an unnatural mastoid cavity which in many cases, despite regular cleansing and topical antimicrobial therapy, persistently discharges. Aimed fundamentally to obtain a smaller, safe and self-cleaning cavity a variety of mastoid obliteration and reconstruction techniques are reviewed, wich involve biologic materials, such as fascial and muscle flaps as well as bone, cartilage and fat grafts. Non-biologic materials include hydroxyapatite crystals, silicone and ceramic glass and are also reviewed. Finally a ceramic hydrogel is presented. Available evidence on its biocompatibility, osteoinductive properties and usability in mastoid reconstruction surgery are discussed. La timpanoplastica aperta rimane l'operazione più comune e meno controversa per il trattamento del colesteatoma, minimizzando il tasso di recidiva. Il risultato è però una cavità mastoidea innaturale che in molti casi, nonostante la pulizia regolare e la terapia antimicrobica topica, rimane problematica. Destinate allo scopo fondamentalmente di ottenere una cavità più piccola, sicura e autopulente, sono state passate in rassegna le varie tecniche di obliterazione e ricostruzione mastoidea, che includono materiali biologici, come lembi fasciali e muscolari, nonché innesti di osso, cartilagine e grasso. Tra i materiali non-biologici si annoverano cristalli di idrossiapatite, silicone e vetroceramica. Infine è stato presentato un idrogel ceramico. Vengono discusse le prove disponibili sulla sua biocompatibilità, proprietà osteoinduttive e usabilità nella chirurgia di ricostruzione mastoidea

Timing of surgery following SARS-CoV-2 infection: an international prospective cohort study

Peri-operative SARS-CoV-2 infection increases postoperative mortality. The aim of this study was to determine the optimal duration of planned delay before surgery in patients who have had SARS-CoV-2 infection. This international, multicentre, prospective cohort study included patients undergoing elective or emergency surgery during October 2020. Surgical patients with pre-operative SARS-CoV-2 infection were compared with those without previous SARS-CoV-2 infection. The primary outcome measure was 30-day postoperative mortality. Logistic regression models were used to calculate adjusted 30-day mortality rates stratified by time from diagnosis of SARS-CoV-2 infection to surgery. Among 140,231 patients (116 countries), 3127 patients (2.2%) had a pre-operative SARS-CoV-2 diagnosis. Adjusted 30-day mortality in patients without SARS-CoV-2 infection was 1.5% (95%CI 1.4-1.5). In patients with a pre-operative SARS-CoV-2 diagnosis, mortality was increased in patients having surgery within 0-2 weeks, 3-4 weeks and 5-6 weeks of the diagnosis (odds ratio (95%CI) 4.1% (3.3-4.8), 3.9% (2.6-5.1) and 3.6% (2.0-5.2), respectively). Surgery performed &gt;= 7 weeks after SARS-CoV-2 diagnosis was associated with a similar mortality risk to baseline (odds ratio (95%CI) 1.5% (0.9-2.1%)). After a &gt;= 7 week delay in undertaking surgery following SARS-CoV-2 infection, patients with ongoing symptoms had a higher mortality than patients whose symptoms had resolved or who had been asymptomatic (6.0% (95%CI 3.2-8.7) vs. 2.4% (95%CI 1.4-3.4) vs. 1.3% (95%CI 0.6-2.0%), respectively). Where possible, surgery should be delayed for at least 7 weeks following SARS-CoV-2 infection. Patients with ongoing symptoms &gt;= 7 weeks from diagnosis may benefit from further delay